Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Systemic Lupus Erythematosus: HELP
Articles by R. Pikman
Based on 1 article published since 2008
||||

Between 2008 and 2019, R. Pikman wrote the following article about Lupus Erythematosus, Systemic.
 
+ Citations + Abstracts
1 Review Neuropsychiatric SLE: from animal model to human. 2017

Pikman, R / Kivity, S / Levy, Y / Arango, M-T / Chapman, J / Yonath, H / Shoenfeld, Y / Gofrit, S G. ·1 Israel Defense Forces Medical Corps, Ramat Gan, Israel. · 2 Department of Medicine A, Sheba Medical Center, Tel-Hashomer, Israel. · 3 The Zabludovicz Center for Autoimmune Diseases. · 4 The Dr Pinchas Borenstein Talpiot Medical Leadership Program 2013; and Sheba Medical Center, Tel-Hashomer, Israel. · 5 Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel. · 6 Department of Medicine E, Meir Medical Center, Kfar Saba, Israel; affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. · 7 Doctoral Program in Biomedical Sciences, Universidad del Rosario, Bogotá-Colombia. · 8 Department of Neurology, Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Israel. · 9 The Danek Gartner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, Israel. · 10 Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel Aviv University, Israel. ·Lupus · Pubmed #28394237.

ABSTRACT: Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed "targeted biological medication" is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease.